EGFR and ovarian carcinoma: In this study, we investigated the mechanism for the limited activity of the EGFR inhibitor, gefitinib, in ovarian cancer cells, and found that increased activity of STAT3 after gefitinib treatment could partially explain the gefitinib resistance.